22:54 , Jan 15, 2019 |  BC Week In Review  |  Clinical News

FDA reviewing Pfizer's TTR amyloid cardiomyopathy therapy

Pfizer Inc. (NYSE:PFE) said FDA accepted for review two NDAs for tafamidis to treat transthyretin (TTR) amyloid cardiomyopathy based on two forms of the compound. The NDA for the tafamidis meglumine form was granted Priority...
20:28 , Jan 14, 2019 |  BC Extra  |  Company News

FDA reviewing Pfizer's TTR amyloid cardiomyopathy therapy

Pfizer Inc. (NYSE:PFE) said FDA accepted for review two NDAs for tafamidis to treat transthyretin (TTR) amyloid cardiomyopathy based on two forms of the compound. The NDA for the tafamidis meglumine form was granted Priority...
19:26 , Dec 21, 2018 |  BC Week In Review  |  Company News

Amgen adds stroma-targeted therapy via Molecular Partners deal

Through a deal with Molecular Partners AG (SIX:MOLN) giving it rights to programs targeting the tumor stroma, Amgen Inc. (NASDAQ:AMGN) will expand its immuno-oncology toolbox beyond tumor antigen-targeted therapies. On Dec. 19, Amgen received exclusive,...
20:21 , Dec 19, 2018 |  BC Extra  |  Company News

Amgen adds stroma-targeted therapy via Molecular Partners deal

Through a deal with Molecular Partners AG (SIX:MOLN) giving it rights to programs targeting the tumor stroma, Amgen Inc. (NASDAQ:AMGN) will expand its immuno-oncology toolbox beyond tumor antigen-targeted therapies. On Wednesday, Amgen received exclusive, worldwide...
17:59 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Roche reports responses for IL-2 variant at ESMO

A targeted IL-2 variant from Roche (SIX:ROG; OTCQX:RHHBY) showed monotherapy activity in patients with metastatic solid tumors in a Phase I trial. Data presented at the European Society for Medical Oncology in Munich from the...
23:49 , Oct 22, 2018 |  BC Extra  |  Clinical News

Roche reports responses for IL-2 variant at ESMO

A targeted IL-2 variant from Roche (SIX:ROG; OTCQX:RHHBY) showed monotherapy activity in patients with metastatic solid tumors in a Phase I trial. Data presented Sunday at the European Society for Medical Oncology in Munich from...
17:27 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

FDA approves hereditary amyloidosis drug from Akcea, Ionis

Akcea Therapeutics Inc. (NASDAQ:AKCA) said FDA approved Tegsedi inotersen (IONIS-TTRRx) to treat polyneuropathy of hereditary transthyretin (TTR) amyloidosis (hATTR). Tegsedi's label includes a black box warning of increased risk for thrombocytopenia and glomerulonephritis. It also...
17:40 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal; cancer

INDICATION: Adenomatous polyps; colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting JAG1 could help treat familial adenomatous polyposis (FAP) and Notch 1-positive, MFNG-negative colorectal cancers. In Notch 1-positive tumor samples from 198...
19:37 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Mouse studies suggest combined inhibition of EGFR and β-catenin could help treat EGFR-mutant NSCLC. In two xenograft mouse models of EGFR-mutant NSCLC, the EGFR inhibitor Tarceva erlotinib and a...
18:47 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Pfizer eyes submission after TTR readout

Pfizer Inc. (NYSE:PFE) reported detailed data from the Phase III ATTR-ACT trial of tafamidis meglumine in patients with transthyretin (TTR) cardiomyopathy showing that the drug led to a 30% improvement in all-cause mortality. Pfizer has...